ClinicalTrials.gg
Active, not recruitingNCT05564130BIHCAUpdated Feb 17, 2026

Bicarbonate for In-Hospital Cardiac Arrest

A Phase 4 interventional study of Sodium bicarbonate and Sodium chloride in Cardiac Arrest, sponsored by Lars Wiuff Andersen. Active, not recruiting at 22 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Lars Wiuff Andersen · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
778
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.

Planned enrollment
10th of 26
778 · median 274
Started
2023
with 1 other
Phase 4
5 of 36
2 open now
Primary completion
2026-02
later than 3 of 10 live
Registered
31st of 36
by date
Lead sponsor
4 of 36
Lars Wiuff Andersen

Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 4, reaches primary completion later than 3 of the 10 other live ones, and was the 31st registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Heart Arrest with a site in Denmark, or all of them as a file.
02

Study summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of sodium bicarbonate during adult in-hospital cardiac arrest. There will be 22 enrolling sites in Denmark. 778 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

03

Conditions studied

  • Cardiac Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In-hospital cardiac arrest
  2. Age ≥ 18 years
  3. Received at least one dose of adrenaline during cardiopulmonary resuscitation (CPR)

Exclusion criteria

Exclusion Criteria:

  1. Clearly documented "do-not-resuscitate" order prior to the cardiac arrest
  2. Prior enrollment in the trial
  3. Invasive mechanical circulatory support at the time of the cardiac arrest
  4. Known or suspected pregnancy at the time of the cardiac arrest
  5. Known objection by the patient to participate in the trial
  6. Clinical indication for bicarbonate administration
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
778 participants (estimated)

Study arms

  • Experimental
    Sodium bicarbonate

    50 ml of 1 mmol/ml sodium bicarbonate given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 ml of 1 mmol/ml sodium bicarbonate will be administered after the second dose of adrenaline dose for a maximum of two doses.

    Drug: Sodium bicarbonate

  • Placebo comparator
    Placebo

    50 mL of 9 mg/mL NaCl ("normal saline") given as soon as possible after the first dose of adrenaline. If the patient remains in cardiac arrest, one additional dose of 50 mL of 9 mg/mL NaCl will be administered after the second dose of adrenaline dose for a maximum of two doses.

    Drug: Sodium chloride

Interventions

  • Sodium bicarbonate 1 mmol/ml

  • DrugSodium chloride

    Sodium chloride 9 mg/mL

06

What researchers measure

Primary outcomes

  1. Number of Participants With Return of Spontaneous Circulation

    Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes

    Time frame: During the cardiac arrest, an average of 20 minutes

Secondary outcomes

  1. Number of Participants That Survived 30 Days

    Time frame: At 30 days

  2. Number of Participants With a Favorable Neurological Outcome at 30 Days

    A favorable neurological outcome will be defined as a modified Rankin Scale score of 0, 1, 2 or 3. The modified Rankin Scale is a 7-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

    Time frame: At 30 days

Other outcomes

  1. Survival

    Time frame: At 90 days, 180 days, and 1 year

  2. Favorable Neurological Outcome

    A favorable neurological outcome will be defined as a modified Rankin Scale score of 0, 1, 2 or 3. The modified Rankin Scale is a 7-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

    Time frame: At 90 days, 180 days, and 1 year

  3. Health-related Quality of Life (EQ-5D-5L)

    The EQ-5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (i.e. a measure of quality of life between 0 and 1).

    Time frame: At 30 days, 90 days, 180 days, and 1 year

  4. Cerebral performance category

    The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

    Time frame: At 30 days, 90 days, 180 days, and 1 year

  5. Sequential Organ Failure Assessment (SOFA) Score

    The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. We will assess both the cardiovascular sub score as well as the overall SOFA score.

    Time frame: At 2, 24, 48 and 72 hours

  6. Hospital Disposition

    Hospital disposition (e.g. home, rehabilitation, nursing home, hospice) will be defined at the time of discharge from the initial acute care hospital.

    Time frame: At hospital discharge, up to 1 year

  7. pH

    Unit: None

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

  8. Standard bicarbonate

    Unit: mmol/L

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

  9. pCO2

    Partial pressure of CO2 in arterial blood. Unit: kPa

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

  10. Potassium

    Unit: mmol/L

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

  11. Calcium

    Unit: mmol/L

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

  12. Sodium

    Unit: mmol/L

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

  13. Lactate

    Unit: mmol/L

    Time frame: Immediately after return of spontaneous circulation, often within 1 hour

07

Study locations

22 sites
08

References and documents

Publications

  • Granfeldt A, Kirkegaard BL, Vallentin MF, Holmberg MJ, Stankovic N, Lind PC, Kjaergaard AG, Houe N, Vested M, Isbye DL, Kristensen CM, Kjaergaard J, Zwisler ST, Lundsfryd SN, Petersen LB, Folke F, Hansen CM, Iversen KK, Schou M, Wiberg S, Riddersholm SJ, Rasmussen BS, Karlsson K, Plovsing RR, Juhl CS, Krag M, Sorensen CD, Kuhne-Qvist P, Oxlund J, Solling CG, Hansen JR, Andersen LPK, Jensen JMS, Itenov TS, Lauritzen M, Pedersen MJ, Nielsen RP, Fjeldsoe-Nielsen H, Mirzada N, Secher N, Espelund US, Eskol JR, Andersen K, Brochner AC, Nedergaard HK, Hansen PM, Henschel W, Walli AR, Sandgaard M, Asferg CL, Ciubotariu A, Rasmussen MHR, Le Breton V, Nielsen LK, Hansen FG, Braendstrup N, Thomsen IK, Sindberg B, Andersen LW; Bicarbonate for In-Hospital Cardiac Arrest (BIHCA) Investigators. Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2026 Jun 11:e2610628. doi: 10.1001/jama.2026.10628. Online ahead of print. PubMed 42273960 ↗

Individual participant data

Plan to share: Yes — Six months after the publication of the last results, all de-identified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete de-identification of the data. Data will be completely anonymized according to Danish law. All relevant trial-related documents, including the protocol, data dictionary, and the main statistical code, will be shared along with the data. There will be no predetermined end date for the data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered. Interested parties will be able to request the data by contacting the principal investigator. Authorship of publications emerging from the shared data will follow standard authorship guidelines from the International Committee of Medical Journal Editors and might or might not include authors from the steering committee depending on the nature of their involvement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Feb 2026, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Oct 3, 2022
StartActual
Feb 6, 2023
Primary completionActual
Feb 11, 2026
CompletionEst.
Feb 11, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564130
Lead sponsor
Lars Wiuff Andersen
Responsible party
Lars Wiuff Andersen (Associate Professor, Aarhus University Hospital) — Sponsor-investigator
First posted
Oct 3, 2022
Start date
Feb 6, 2023
Primary completion
Feb 11, 2026
Completion
Feb 11, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Lars W Andersen
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Bicarbonate

Start the discussion